-
The original intention is like a torch, hard work is like sail, leukemia and lymphoma special session 1 focuses on the frontier The Harbin branch of the 2022 CSCO Academic Annual Conference
Time of Update: 2023-01-06
Click to read the original article to see more conference videosProfessor Zhang Huilai of Tianjin Medical University Cancer Hospital gave a report entitled "The New Era of Lymphoma Immunotherapy: Breakthroughs and Challenges in Immune Checkpoint Research" from multiple dimensions such as immune dysregulation mechanism and immunotherapy methods.
-
Professor Qiu Lin: Dynamic monitoring of mutant genes, NGS to help AML personalized precision treatment| the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Next-generation sequencing (NGS) plays an important role in the prognosis analysis, efficacy evaluation, recurrence prediction and detection of minimal residual disease (MRD) in acute myeloid leukemia
-
Research Express! Iberdomide in combination with dexamethasone in the treatment of advanced R/R MM is a new progress
Time of Update: 2023-01-06
Multiple myeloma (MM) is characterized by the persistence of minimal residual disease during combination therapy by patients, leading to multiple cycles of remission and recurrence. Each subsequent li
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Case evaluation Professor Hou Ming: The combination of two swords and walls has begun to show strength, the blade out of the sheath to accurately block elderly AML, and the treatment of FLT3 mutant AML by geratinib can be expected in the future
Time of Update: 2023-01-06
05×10 9/L, HGB 54g/L, PLT 7×109/L, combined with pulmonary infection, cardiac insufficiency, treated with meropenem, tigecycline, voriconazole, improved, and considered adjusting the 。Myelocytology: CRFlow cytometry: abnormal myeloid cells < 0.
-
Professor Georg Lenz: Exploring the revolution in DLBCL first-line treatment
Time of Update: 2023-01-06
Question 2: Before Pola reimbursement, what do you think is the most suitable treatment population for untreated DLBCL patients?Professor Georg LenzFrom subgroup analysis data, Pola-R-CHP regimens showed more significant benefit in patients with high-risk factors such as IPI score 3 to 5, age > 60 years, double expression, and ABC subtype, and may be biased towards these patients before reimbursement.
-
Professor Li Fei: Seliniso rises to the challenge and breaks the dilemma of multiple myeloma recurrence and incurability!
Time of Update: 2023-01-06
The Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (2022 Revision)5 points out that 3-4 drugs containing proteasome inhibitors, immunomodulators, daratumumab and nuclear output protein inhibitor celinisol can be selected as much as possible, and salvage autologous hematopoietic stem cell transplantation (ASCT) can be performed if possible 。 BOSTON STUDY7 SHOWED THAT THE MEDIAN PFS IN THE CELINISO PLUS BORTEZOMIB AND DEXAMETHASONE (VD) GROUPS WAS SIGNIFICANTLY LONGER THAN IN THE BORTEZOMIB PLUS DEXAMETHASONE (VD) GROUP (PFS: 13.
-
JCO(IF=51) Shanghai Jiao Tong University multi-unit cooperation, Academician Pei Zhengkang's team found that CAR-T therapy is safe and effective in the treatment of relapsed or refractory B acute lymphoblastic leukemia
Time of Update: 2023-01-06
iNatureIt is unclear whether combination therapy with CD19 and CD22 chimeric antigen receptor T cells leads to durable event-free survival in children with refractory disease or high-risk B acute lymp
-
Professor Huang Wenrong: Progress in first-line induction and consolidation therapy for primary central nervous system lymphoma The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Professor Huang Wenrong said that previous prospective studies have proved that ASCT and whole-brain radiotherapy can significantly improve the median progression-free survival (PFS) of patients with first-line therapy remission of PCNSL compared with non-myeloablative high-dose consolidation chemotherapy.
-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
The treatment of MM with extramedullary disease gradually improved, and CD38 monoclonal antibody was successfully shortlisted
Time of Update: 2023-01-06
Table 2 RRMM phase II trial results for Dara-DCEP treatment with EMDA study of 24 patients (14 patients, Isa-Pd; 10 cases, Pd) and 19 (12 cases, Isa-Kd; 7 cases, Kd) patients with soft tissue plasmacytoma were analyzed after the fact6, and the prospect of Isatuximab in MM with EMD was also observed 。 The study showed that at a median follow-up of 18.
-
Can autologous hematopoietic stem cell transplantation after first-line therapy prolong the survival of patients with stage II-IV peripheral T-cell lymphoma < 65 years of age?
Time of Update: 2023-01-06
Poke "Read Original" to see moreIn this large study, researchers observed a significant increase in OS rates in patients with advanced PTCL over the past 20 years, but the prognosis remains poor.
-
Can autologous hematopoietic stem cell transplantation after first-line therapy prolong the survival of patients with stage II-IV peripheral T-cell lymphoma < 65 years of age?
Time of Update: 2023-01-06
Poke "Read Original" to see moreIn this large study, researchers observed a significant increase in OS rates in patients with advanced PTCL over the past 20 years, but the prognosis remains poor.
-
Feifan Blood Cloud Classroom November Myeloma Literature Intensive Reading Workshop
Time of Update: 2023-01-06
discussThis study is the largest RRMM WGS data analysis to date (616 total patients) and provides the most comprehensive RRMM genome-wide analysis to date, identifying new RRMM driver genes through coding and noncoding region variants of the genome.
-
Feifan Blood Cloud Classroom November Myeloma Literature Intensive Reading Workshop
Time of Update: 2023-01-06
discussThis study is the largest RRMM WGS data analysis to date (616 total patients) and provides the most comprehensive RRMM genome-wide analysis to date, identifying new RRMM driver genes through coding and noncoding region variants of the genome.
-
"Artificial red blood cells" are used in human trials for the first time! Or will revolutionize the treatment of patients with blood disorders!
Time of Update: 2023-01-06
The UK's National Health Service (NHS) has launched a clinical trial with research institutions such as the University of Bristol to inject laboratory-grown red blood cells into humans for the first time.
-
Iron deficiency anemia and thrombocytosis pair CP
Time of Update: 2023-01-06
SometimeYou met a child considering iron deficiency anemia in the outpatient clinic, but found that the platelet count on the blood routine report also increased significantly, could it be another blood disease?
-
Iron deficiency anemia and thrombocytosis pair CP
Time of Update: 2023-01-06
SometimeYou met a child considering iron deficiency anemia in the outpatient clinic, but found that the platelet count on the blood routine report also increased significantly, could it be another blood disease?
